Raaj Medisafe Intrinsic Value
Raaj Medisafe intrinsic value. Raaj Medisafe (RAAJMEDI) median intrinsic value is ₹36.36 from 8 valuation models (range ₹29–₹53), vs current price ₹102.98 — -64.7% downside (Trading Above Calculated Value), margin of safety -100.0%. Compare with RAAJMEDI fair value to assess whether the stock is under or overvalued.
RAAJMEDI Valuation Methods Summary — DCF, Graham Number & P/E
Raaj Medisafe intrinsic value across 8 models vs current price ₹102.98 — upside/downside and value range per method. Read RAAJMEDI dividend track record for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹30.89 | ₹24.71 - ₹37.07 | -70.0% | EPS: ₹2.00, Sector P/E: 12x |
| Book Value Method | asset | ₹29.38 | ₹26.44 - ₹32.32 | -71.5% | Book Value/Share: ₹29.38, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹47.00 | ₹42.30 - ₹51.70 | -54.4% | Revenue/Share: ₹58.75, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹52.50 | ₹47.25 - ₹57.75 | -49.0% | EBITDA: ₹14.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹41.19 | ₹32.95 - ₹49.43 | -60.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹30.89 | ₹27.80 - ₹33.98 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹30.89 | ₹27.80 - ₹33.98 | -70.0% | Revenue Growth: 15.0%, Adj P/E: 8.6x |
| Graham Defensive Method | conservative | ₹36.36 | ₹32.72 - ₹40.00 | -64.7% | EPS: ₹2.00, BVPS: ₹29.38 |
RAAJMEDI Intrinsic Value vs Market Price — All Valuation Models
Raaj Medisafe fair value range ₹29–₹53 vs current market price ₹102.98 across 8 valuation models. For current market price and key ratios, visit RAAJMEDI screener.
RAAJMEDI Intrinsic Value Analysis — Undervalued or Overvalued?
Raaj Medisafe median intrinsic value ₹36.36, current price ₹102.98 — Trading Above Calculated Value by 64.7%, margin of safety -100.0%.
What is the intrinsic value of RAAJMEDI?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Raaj Medisafe (RAAJMEDI) is ₹36.36 (median value). With the current market price of ₹102.98, this represents a -64.7% variance from our estimated fair value.
The valuation range spans from ₹29.38 to ₹52.50, indicating ₹29.38 - ₹52.50.
Is RAAJMEDI undervalued or overvalued?
Based on our multi-method analysis, Raaj Medisafe (RAAJMEDI) appears to be trading above calculated value by approximately 64.7%.
RAAJMEDI Financial Health — Key Ratios vs Industry Benchmarks
Raaj Medisafe financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.31 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 4.3% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 14.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.78x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
RAAJMEDI Cash Flow Quality — Operating & Free Cash Flow
Raaj Medisafe operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹4 Cr | ₹-14 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹0 Cr | ₹-8 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹4 Cr | ₹-3 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹0 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |